Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) traded up 2% on Thursday. The stock traded as high as $3.60 and last traded at $3.60. 3,200 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 13,145 shares. The stock had previously closed at $3.53.
Medexus Pharmaceuticals Stock Performance
The company has a 50-day moving average of $3.56 and a 200 day moving average of $2.97.
Medexus Pharmaceuticals Company Profile
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company focused on acquiring, commercializing and supporting differentiated prescription products in North America. The company serves healthcare providers and patients primarily in the United States and Canada, with an emphasis on products addressing specialty and underserved therapeutic markets.
Medexus’ portfolio has included IXINITY, a recombinant factor IX replacement therapy used to prevent and control bleeding in people with hemophilia B; Rasuvo, a single-dose subcutaneous methotrexate injection used for certain rheumatoid arthritis and juvenile idiopathic arthritis patients; and Gleolan, an oral diagnostic imaging agent used during surgery to help visualize malignant glioma tissue.
The company’s business model is centered on licensing, acquiring and commercializing pharmaceutical products rather than conducting broad-based drug discovery.
Further Reading
- Five stocks we like better than Medexus Pharmaceuticals
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
